Moleculin Biotech Terminates Clinical Trial
Moleculin Biotech has halted a Phase 1 trial on anvandinostat for acute lymphoblastic leukemia due to futility, according to the 8-K filing.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed